Age-dependent differences in the immune response to human metapneumovirus
对人类偏肺病毒的免疫反应存在年龄依赖性差异
基本信息
- 批准号:10700837
- 负责人:
- 金额:$ 4.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-15 至 2027-08-14
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAdoptive TransferAgeAlveolar MacrophagesBioinformaticsBiological AssayBody Weight decreasedBone MarrowCD8-Positive T-LymphocytesCD8B1 geneCell CommunicationCellsChestChildChimera organismClinicalCoculture TechniquesColorCommunicable DiseasesDataDevelopmentDichloromethylene DiphosphonateDiseaseElderlyEpigenetic ProcessExhibitsFlow CytometryFunctional disorderFundingGenesGenetic TranscriptionGoalsHospitalizationHuman MetapneumovirusImmuneImmune responseImmunityImmunocompromised HostImmunologicsImmunologyImpairmentIn VitroInfectionInflammatoryInfluenzaIsogenic transplantationKnowledgeLabelLaboratoriesLiposomesLiteratureLongevityLower Respiratory Tract InfectionLungMacrophageMediatorMolecular TargetMorbidity - disease rateMusNatural ImmunityNeonatalPathogenesisPathway interactionsPersonsPopulationPopulations at RiskPredispositionPreventionPrimary InfectionPrincipal InvestigatorPulmonary InflammationReportingResearchResearch PersonnelRespiratory DiseaseRespiratory Tract InfectionsRespiratory syncytial virusRoleScientistSeasonsSeveritiesSeverity of illnessSignal TransductionT cell responseT-LymphocyteTechnical ExpertiseTestingTissuesTrainingTranslatingVaccinesViralVirusVirus ReplicationVulnerable PopulationsWeight GainWestern Blottingadaptive immunityage relatedagedcandidate identificationcareercell typechromatin modificationclinical translationcytokineexperimental studyfunctional disabilityimmunoregulationimprovedmonocytemortalitymouse modelmultiple omicsneutralizing antibodynovelpreventprogrammed cell death protein 1reconstitutionrespiratoryrespiratory pathogenrespiratory virussecondary infectionsecondary lymphoid organskillstooltraining opportunity
项目摘要
ABSTRACT
Human metapneumovirus (HMPV) is a leading cause of lower respiratory infections in young children,
immunocompromised persons, and the elderly, resulting in high morbidity and mortality. Few studies have
investigated why HMPV is more severe in the elderly. This proposal aims to fill this knowledge gap about
HMPV pathogenesis. My preliminary data discovered that aged mice infected with HMPV exhibit delayed viral
clearance, increased lung inflammation, and increased CD8+ HMPV-tetramer+ cells co-expressing the
inhibitory markers PD-1, TIM-3, and LAG-3. I hypothesize that severe HMPV infection in the elderly is
caused by impairment of the CD8+ T cell response. In Aim 1, I will investigate the intrinsic causes of the
CD8+ T cell impairment observed in the aged host infected with HMPV using 10X Multiomics studies on murine
lung directly ex vivo and syngeneic transplants. 10X Multiomics will elucidate age-related epigenetic changes
in CD8+ T cells while syngeneic transplants will transfer young CD8+ T cells into an aged host and vice versa to
determine if CD8+ T cells are the primary immune cells causing the impaired immune response to HMPV (i.e.
increased weight loss, clinical severity, delayed viral clearance). In Aim 2, I will investigate extrinsic causes of
the CD8+ T cell impairment, namely by alveolar macrophages (AMs). I will use a 21-color multispectral flow
cytometry panel to enumerate M1 and M2 macrophage populations in the aged host. In vitro co-culture and
transwell assays of AMs and CD8+ T cells will determine if AMs directly impair CD8+ T cells. Selective depletion
of AMs in aged mice and adoptive transfer of young macrophages will determine how AMs contribute to the
impaired immune response in the aged host. 10X Multiomics will also be performed in this aim to investigate
the age-related epigenetic changes in AMs that may contribute to their aberrant M2 accumulation, which I have
also observed in my preliminary data.
This proposal aims to understand the mechanistic differences in the aged host response to HMPV,
which will help elucidate why HMPV infection in the elderly is more severe. These studies have the potential to
translate into the clinical setting and contribute to better management and treatment for HMPV infection, such
as immunomodulation. Identifying molecular targets in the aged host will guide development of a safe and
effective vaccine against HMPV for all at-risk populations.
In addition, this proposal has tremendous training opportunities, contributing towards my career goals of
becoming a clinician scientist and independent principal investigator in immunology and infectious disease.
摘要
人偏肺病毒(HMPV)是幼儿下呼吸道感染的主要原因,
免疫功能低下的人和老年人,导致高发病率和死亡率。很少有研究
研究了为什么HMPV在老年人中更严重。该提案旨在填补这一知识空白,
HMPV发病机制。我的初步数据发现,感染HMPV的老年小鼠表现出延迟的病毒性,
清除,增加肺部炎症,增加共表达HMPV-四聚体的CD 8 + HMPV-四聚体+细胞
抑制性标志物PD-1、TIM-3和LAG-3。我假设老年人严重的HMPV感染是
由CD 8 + T细胞反应受损引起。在目标1中,我将调查
使用10 X Multiomics研究在感染HMPV的老年宿主中观察到的小鼠CD 8 + T细胞损伤
肺直接离体和同基因移植。10 X Multiomics将阐明与年龄相关的表观遗传变化
在CD 8 + T细胞中,而同基因移植将年轻的CD 8 + T细胞转移到老年宿主中,反之亦然,
确定CD 8 + T细胞是否是导致对HMPV的免疫应答受损的主要免疫细胞(即,
体重减轻增加、临床严重程度、病毒清除延迟)。在目标2中,我将调查
CD 8 + T细胞损伤,即肺泡巨噬细胞(AM)。我会用21色多光谱流
使用流式细胞术板计数老年宿主中的M1和M2巨噬细胞群体。体外共培养和
AM和CD 8 + T细胞的transwell测定将确定AM是否直接损害CD 8 + T细胞。选择性消耗
老年小鼠中AM的数量和年轻巨噬细胞的过继转移将决定AM如何促进
老年宿主的免疫反应受损还将进行10 X Multiomics,以研究
AM中与年龄相关的表观遗传变化可能导致其异常的M2积累,我已经
这也是我的初步数据。
该建议旨在了解老年宿主对HMPV反应的机制差异,
这将有助于阐明为什么老年人中HMPV感染更严重。这些研究有可能
转化为临床环境,并有助于更好地管理和治疗HMPV感染,
免疫调节。鉴定老年宿主中的分子靶点将指导开发安全且
为所有高危人群提供有效的HMPV疫苗。
此外,这份建议书提供了大量的培训机会,有助于实现我的职业目标,
成为临床科学家和免疫学和传染病的独立首席研究员。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Olivia Parks其他文献
Olivia Parks的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Olivia Parks', 18)}}的其他基金
Age-dependent differences in the immune response to human metapneumovirus
对人类偏肺病毒的免疫反应存在年龄依赖性差异
- 批准号:
10462114 - 财政年份:2022
- 资助金额:
$ 4.94万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 4.94万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 4.94万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 4.94万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 4.94万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 4.94万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 4.94万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 4.94万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 4.94万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 4.94万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 4.94万 - 项目类别:














{{item.name}}会员




